Eli Lilly has agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash. The drugmaker said Monday it is acquiring Scorpion and its STX-478 program ...

As part of the deal, Eli Lilly will acquire Scorpion's STX-478, an investigative once-daily oral medication being evaluated in a trial. Scorpion would spin out its non-phosphoinositide 3-kinase ...

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in a third major transaction announced on the first day of the JP Morgan ...

Leerink lowered the firm’s price target on Recursion Pharmaceuticals (RXRX) to $6 from $7 and keeps a Market Perform rating on the shares after ...

The UK-headquartered pharma is buying into a drug discovery platform developed by Boston, US biotech Scorpion Therapeutics, paying $75 million upfront to get the ball rolling on the partnership ...

In a significant move to bolster its pipeline and capabilities, Relay Therapeutics acquired Scorpion Therapeutics in early 2025 for $2.5 billion in cash. This acquisition is viewed by analysts as ...

AstraZeneca’s partnership with Scorpion Therapeutics will focus on transcription factors that are known to play a role in cancer but have been difficult to target with small molecule drugs.

The announcement comes just one month after Lilly said it would be expanding its oncology pipeline by acquiring Scorpion Therapeutics’ PI3Kα inhibitor programme in a deal worth up to $2.5bn. STX-478 ...

Two recent high-profile acquisitions exemplify this trend; Eli Lilly’s pursuit of Scorpion Therapeutics and GSK’s acquisition of IDRx. Eli Lilly’s Bold Bid to Lead Oncology Eli Lilly’s ...

Additionally, the recent acquisition of Scorpion by Lilly for a significant ... Begin your TipRanks Premium journey today. Relay Therapeutics (RLAY) Company Description: Relay Therapeutics Inc ...

In a significant move to bolster its pipeline and capabilities, Relay Therapeutics acquired Scorpion Therapeutics in early 2025 for $2.5 billion in cash. This acquisition is viewed by analysts as a ...